Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics (NQ: HZNP )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Horizon Therapeutics

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Data Presented from the MIRROR Randomized Controlled Trial Demonstrate KRYSTEXXA® (pegloticase injection) Plus Methotrexate Resulted in Significant Improvement in Efficacy and Safety (Infusion Reactions) Compared to KRYSTEXXA Monotherapy
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Wins 2022 International CSR Excellence Award for #RAREis Adoption Fund
From Horizon Therapeutics plc
Via Business Wire
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
4 Analysts Have This to Say About Horizon Therapeutics
Horizon Therapeutics (NASDAQ:HZNP) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Analysis from the Phase 3 N-MOmentum Study Demonstrates the Effectiveness of UPLIZNA® (inebilizumab-cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations
From Horizon Therapeutics plc
Via Business Wire
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for... 
Via Benzinga
Horizon Therapeutics plc to Present MIRROR Randomized Controlled Trial Primary Endpoint Data at The EULAR 2022 European Congress of Rheumatology
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics: Q1 Earnings Insights
Horizon Therapeutics (NASDAQ:HZNP) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Horizon Therapeutics' Inebilizumab Scores European Approval For Spinal Cord Inflammation
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022
Upgrades 
Via Benzinga
Horizon Therapeutics Earnings Perspective: Return On Capital Employed
According to Benzinga Pro, during Q1, Horizon Therapeutics (NASDAQ:HZNP) earned $204.26 million, a 17.95% increase from the preceding quarter. Horizon Therapeutics's sales decreased to $885.25 million,... 
Via Benzinga
Horizon Therapeutics Begins Patient Enrolment in Phase 2 trial of Daxdilimab (HZN-7734) for Alopecia Areata
Horizon Therapeutics plc (NASDAQ: HZNP) enrolled first patient in a Phase 2, open-label, proof-of-concept trial of its drug candidate Daxdilimab (HZN-7734) to treat people with moderate-to-severe... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
Via Benzinga
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Ranked Second in Overall Corporate Reputation in U.S. PatientView Survey of Patient Groups
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Dara Mann as a Healthcare Businesswomen’s Association 2022 Rising Star
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head On
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics and Chicago Sky Announce Multi-Year Partnership
From Horizon Therapeutics
Via Business Wire
Stock Market Jumps, Then Dives After Fed Rate Hikes As Treasury Yields Soar: Weekly Review
Lithium plays jump on earnings, but Nasdaq at lowest level since 2020. 
Via Investor's Business Daily
Horizon Therapeutics plc Reports First-Quarter 2022 Financial Results
From Horizon Therapeutics plc
Via Business Wire
Topline Data for Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Launches #RAREis Global Advocate Grant Program to Support the Rare Disease Community
From Horizon Therapeutics plc
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Higher Following Friday's Sell-Off
Pre-open movers 
Via Benzinga
Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Will Investors Notice Exciting Sign On Horizon Therapeutics's Chart?
If history is any guide, there may be good fortune ahead for shares of Horizon Therapeutics (NASDAQ:HZNP). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
Horizon Therapeutics plc Among Top Companies for Overall Corporate Reputation in 2021 Global PatientView Survey of Patient Groups Worldwide
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics and Massachusetts Institute of Technology (MIT) Solve Announce Second Annual Horizon Prize to Inspire Solutions that Improve the Quality of Life for the Global Rare Disease Community
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Release First-Quarter 2022 Financial Results and Host Webcast on May 4, 2022
From Horizon Therapeutics plc
Via Business Wire
Eton Pharmaceuticals Names James Gruber Finance Chief
Eton Pharmaceuticals Inc (NASDAQ: ETON) has appointed James Gruber as Chief Financial Officer effective immediately. He succeeds Wilson Troutman, who is retiring.... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.